Thus, BITC is a strong anti-cancer agent effective against pancreatic cancer acting via inhibition of PI3K/AKT/FOXO-, STAT-3-, and STAT-3-mediated HIF-1α/VEGF/Rho-GTPases signaling axes. Here, AKT1 is linked to pancreatic neoplasm.